Behind Canada’s current COVID-19 vaccine shortage is a decades-long tale of unheeded warnings, missed opportunities and dismantled resources that was never going to end well.
Academic rigor, journalistic flair
Articles on biopharmaceutical industry
Displaying all articles
Clinton, who named drug companies among her enemies in this week’s debate, is pushing populist-inspired policies that could hamper the flow of new medicines.
Before the last round of negotiations, only a handful of issues remained in the way of concluding the TPP. A potential deal-breaker for Australia was intellectual property protections for biologics.
Top contributors
-
Adjunct professor, Department of Health Policy & Management, George Washington University
-
Lecturer in Accounting & Management, Lancaster University
-
Joel Lexchin is a Friend of The Conversation.
Professor Emeritus of Health Policy and Management, York University, Canada
